AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9365351 — intervention group
Group type: COMPARATOR
Intervention: Subjects with disc herniation (27 subjects)
Number of subjects: 60
Study 1585959 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative weight gain prevention intervention
Number of subjects: 158
Study 1585959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific treatment
Number of subjects: 158
Study 1585959 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 158
Study 3898891 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol chemical sympathectomy
Number of subjects: 41
Study 3898891 — intervention group
Group type: COMPARATOR
Intervention: Placebo bupivacaine injection
Number of subjects: 41
Study 30458732 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment with a non-steroidal aromatase inhibitor combined with CDK4/6 inhibition, followed on progression by fulvestrant
Number of subjects: 1050
Study 30458732 — intervention group
Group type: COMPARATOR
Intervention: First-line treatment with a non-steroidal aromatase inhibitor, followed on progression by fulvestrant combined with CDK4/6 inhibition
Number of subjects: 1050
Study 30458732 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival, safety, quality of life, and cost-effectiveness
Number of subjects: 1050
Study 26875070 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion lymph node dissection (CLND)
Number of subjects: 556
Study 26875070 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 556
Study 25277144 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (400-1,800 µg, twice daily for 3 days)
Number of subjects: 16
Study 25277144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 16
Study 22402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 25 mg/week and prednisone 60 mg/day tapered to 7.5 mg/day in 7 weeks
Number of subjects: 610
Study 20802246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4662
Study 17297026 — intervention group
Group type: COMPARATOR
Intervention: Primaquine 210 mg
Number of subjects: 0
Study 17297026 — intervention group
Group type: COMPARATOR
Intervention: Primaquine 315 mg
Number of subjects: 0
Study 17297026 — intervention group
Group type: COMPARATOR
Intervention: Primaquine 420 mg
Number of subjects: 0
Study 17297026 — intervention group
Group type: COMPARATOR
Intervention: Weight-based primaquine dose
Number of subjects: 0
Study 15287405 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh tourniquet
Number of subjects: 32
Study 15287405 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 32
Study 11685933 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0
Study 9158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection alone
Number of subjects: 276
Study 9158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection plus heat probe treatment
Number of subjects: 276
Study 9158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection alone (subgroup with spurting haemorrhage)
Number of subjects: 276
Study 9158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection plus heat probe treatment (subgroup with spurting haemorrhage)
Number of subjects: 276
Study 8260854 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid (fluticasone propionate [FP] 100 micrograms twice daily)
Number of subjects: 28
Study 8260854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating test (high-carbohydrate meal)
Number of subjects: 16
Study 3630936 — intervention group
Group type: COMPARATOR
Intervention: Control test (water)
Number of subjects: 16
Study 30728488 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab + PRP
Number of subjects: 49
Study 30728488 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab only
Number of subjects: 49
Study 29114088 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Onyx embolization
Number of subjects: 61
Study 27690510 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution hints available
Number of subjects: 476
Study 27690510 — intervention group
Group type: COMPARATOR
Intervention: No solution hints available
Number of subjects: 476
Study 25133962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 352
Study 25133962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 352
Study 25133962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 22287677 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine and glucosamine‐chondroitin
Number of subjects: 0
Study 22287677 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen
Number of subjects: 0
Study 22287677 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken cartilage
Number of subjects: 0
Study 22287677 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit hair, skin, and bone
Number of subjects: 0
Study 22287677 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen and rabbit bone
Number of subjects: 0
Study 19650913 — intervention group
Group type: EXPERIMENTAL
Intervention: PhysioDirect
Number of subjects: 1875
Study 19650913 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1875
Study 18077302 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention (BAI)
Number of subjects: 367
Study 18077302 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) skills
Number of subjects: 367
Study 18077302 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient speech during BAI
Number of subjects: 367
Study 16781588 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630 (30 drops three times daily for seven days)
Number of subjects: 124
Study 16781588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 drops three times daily for seven days)
Number of subjects: 124
Study 16781588 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 124
Study 16781588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 12137074 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative interdisciplinary care
Number of subjects: 279
Study 12137074 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study 10053226 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 116
Study 10053226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 7475819 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi pallidotomy
Number of subjects: 14
Study 2253927 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone 0.1g t.i.d.
Number of subjects: 72
Study 2253927 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.2g t.i.d.
Number of subjects: 72
Study 2253927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 6106612 — intervention group
Group type: EXPERIMENTAL
Intervention: Halazepam 120 mg
Number of subjects: 0
Study 6106612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6106612 — intervention group
Group type: COMPARATOR
Intervention: Halazepam 60 mg
Number of subjects: 0
Study 31157583 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐DM1+P
Number of subjects: 444
Study 31157583 — intervention group
Group type: COMPARATOR
Intervention: TCH+P
Number of subjects: 444
Study 28241328 — intervention group
Group type: EXPERIMENTAL
Intervention: Spencer technique
Number of subjects: 15
Study 28241328 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 15
Study 25351610 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 121
Study 25351610 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 121
Study 23276482 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 323
Study 21434337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuanxin Capsule (NXC)
Number of subjects: 150
Study 21434337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19376452 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (1500 mg per day)
Number of subjects: 635
Study 19376452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 19839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin-acetylsalicylic acid combination
Number of subjects: 5
Study 19839182 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 5
Study 15117729 — intervention group
Group type: EXPERIMENTAL
Intervention: NFEV(1) (FEV(1) corrected for gas compression)
Number of subjects: 0
Study 15117729 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1)
Number of subjects: 0
Study 15117729 — intervention group
Group type: EXPERIMENTAL
Intervention: NFEV(1)
Number of subjects: 0
Study 11920767 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol matrix patch (first patch worn for 4 days, second for 3 days, third for 4 days)
Number of subjects: 16
Study 11920767 — intervention group
Group type: COMPARATOR
Intervention: 17-beta-estradiol matrix patch (control group without E(2) pretreatment)
Number of subjects: 16
Study 9672184 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha2a (with or without ribavirin)
Number of subjects: 3
Study 8004359 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg) alone
Number of subjects: 7
Study 8004359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) with Sho‐saiko‐to (TJ‐9)
Number of subjects: 7
Study 8004359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) with Rikkunshi‐to (TJ‐43)
Number of subjects: 7
Study 8004359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) with Sairei‐to (TJ‐114)
Number of subjects: 7
Study 2620951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron-dextran complex
Number of subjects: 0
Study 2620951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron-dextran complex
Number of subjects: 0
Study 831964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural analgesia
Number of subjects: 0
Study 831964 — intervention group
Group type: COMPARATOR
Intervention: No regional analgesia (Control)
Number of subjects: 0
Study 31442535 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer deep-dermal suturing technique
Number of subjects: 49
Study 31442535 — intervention group
Group type: COMPARATOR
Intervention: Conventional bilayered closure technique
Number of subjects: 49
Study 28850600 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without fusion
Number of subjects: 142
Study 28850600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion by cage standalone
Number of subjects: 142
Study 28850600 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc prosthesis
Number of subjects: 142
Study 28850600 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 142
Study 1533832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbotrain
Number of subjects: 216
Study 1533832 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 216
Study 22882007 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival 1.25 mg/0.05 mL of bevacizumab at the end of surgery (Group 2)
Number of subjects: 41
Study 22882007 — intervention group
Group type: COMPARATOR
Intervention: Pterygium excision with conjunctivo‐limbal autograft (Group 1)
Number of subjects: 41
Study 20511258 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiates
Number of subjects: 1052
Study 20511258 — intervention group
Group type: COMPARATOR
Intervention: Nitrates
Number of subjects: 1052
Study 20511258 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 1052
Study 18194593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose medical food emulsion (0.75 g GLA + 0.5 g EPA)
Number of subjects: 100
Study 18194593 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medical food emulsion (1.13 g GLA + 0.75 g EPA)
Number of subjects: 100
Study 18194593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose medical food emulsion (EFF1009)
Number of subjects: 100
Study 18194593 — intervention group
Group type: COMPARATOR
Intervention: Placebo emulsion
Number of subjects: 100
Study 16407665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone (1 approximately 3 mg/kg/day for 3 days)
Number of subjects: 62
Study 16407665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravenous prednisolone)
Number of subjects: 62
Study 12888140 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 10569964 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 feeds of cows' milk per day
Number of subjects: 262
Study 10569964 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 feeds of cows' milk per day
Number of subjects: 262
Study 10569964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 262
Study 8912147 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (40 mg)
Number of subjects: 18
Study 8912147 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (80 mg)
Number of subjects: 18
Study 1756847 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0
Study 1756847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6337700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG (120 mg in 50 ml saline) administered weekly for 6 weeks
Number of subjects: 69
Study 6337700 — intervention group
Group type: COMPARATOR
Intervention: TUR alone (control group)
Number of subjects: 69
Study 31787586 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/d
Number of subjects: 0
Study 31787586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29898748 — intervention group
Group type: EXPERIMENTAL
Intervention: One three-hour education course on psychological stresses and management skills
Number of subjects: 290
Study 29898748 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no additional education course)
Number of subjects: 290
Study 26499756 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (12.5 g)
Number of subjects: 27
Study 26499756 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (50 g)
Number of subjects: 27
Study 26499756 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (75 g)
Number of subjects: 27
Study 26499756 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (100 g)
Number of subjects: 27
Study 26499756 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink (20 g)
Number of subjects: 27
Study 26499756 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 27
Study 24374803 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 0.5 g/kg
Number of subjects: 60
Study 24374803 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 60
Study 24374803 — intervention group
Group type: COMPARATOR
Intervention: 18AA‐II solution
Number of subjects: 60
Study 22327223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell trait (HbAS)
Number of subjects: 601
Study 19019364 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 120
Study 19019364 — intervention group
Group type: COMPARATOR
Intervention: ERC
Number of subjects: 120
Study 17978250 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 546
Study 17978250 — intervention group
Group type: COMPARATOR
Intervention: Other vocational services
Number of subjects: 546
Study 16685547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg day(-1))
Number of subjects: 9
Study 16685547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15054729 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational self-management intervention (booklet)
Number of subjects: 209
Study 15054729 — intervention group
Group type: COMPARATOR
Intervention: No booklet (control group)
Number of subjects: 209
Study 10781923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg, Ketalar)
Number of subjects: 17
Study 10781923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8834420 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (average dose = 9.0 mg/day sublingually)
Number of subjects: 86
Study 8834420 — intervention group
Group type: COMPARATOR
Intervention: Methadone (average dose = 54 mg/day orally)
Number of subjects: 86
Study 8834420 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 86
Study 8834420 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 86
Study 1432467 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg/kg body weight/day) for 2 weeks
Number of subjects: 301
Study 1432467 — intervention group
Group type: COMPARATOR
Intervention: Placebo in multivitamin syrup for 2 weeks
Number of subjects: 301
Study 1432467 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 301
Study 3901357 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0
Study 3901357 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 0
Study 3901357 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study 31107900 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral physical activity intervention
Number of subjects: 202
Study 28135389 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly telephone intervention problem solving (TIPS)
Number of subjects: 105
Study 28135389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 25956257 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Telemedicine (ITM)
Number of subjects: 566
Study 25956257 — intervention group
Group type: COMPARATOR
Intervention: Phone counseling
Number of subjects: 566
Study 23966217 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey plus coffee (HC)
Number of subjects: 97
Study 23966217 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid (S)
Number of subjects: 97
Study 23966217 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - Guaifenesin
Number of subjects: 97
Study 23966217 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between HC and S
Number of subjects: 97
Study 21222132 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise of the elbow flexors (6 sets of 10 contractions at 120% of voluntary concentric maximum)
Number of subjects: 14
Study 21222132 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise of the elbow flexors
Number of subjects: 14
Study 19126319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S™ and misoprostol combination
Number of subjects: 25
Study 17606053 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 injection of injectable mixed subtype collagenase
Number of subjects: 35
Study 17606053 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 injections of injectable mixed subtype collagenase
Number of subjects: 35
Study 17606053 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study 17606053 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label extension phase with injectable mixed subtype collagenase
Number of subjects: 35
Study 17606053 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with injectable mixed subtype collagenase
Number of subjects: 35
Study 15478484 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride (NaF) bioerodible gel
Number of subjects: 36
Study 15478484 — intervention group
Group type: COMPARATOR
Intervention: Control gel (no treatment)
Number of subjects: 36
Study 11513310 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Recumbent Stepper (TBRS) training 3 days a week for 12 weeks, intensity progressed from 50% HRRmax for 20 min to 75% HRRmax for 40 min
Number of subjects: 26
Study 11513310 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Recumbent Stepper (TBRS) training
Number of subjects: 26
Study 11513310 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study 9633801 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 24
Study 9633801 — intervention group
Group type: EXPERIMENTAL
Intervention: carvedilol
Number of subjects: 24
Study 8018000 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1889
Study 8018000 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1889
Study 8018000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg)
Number of subjects: 1889
Study 8018000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 1889
Study 8018000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (combined)
Number of subjects: 1889
Study 8018000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1889
Study 3111508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1
Number of subjects: 44
Study 3111508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 40 micrograms kg‐1
Number of subjects: 44
Study 3111508 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 and 40 micrograms kg‐1
Number of subjects: 44
Study 3111508 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study 31034336 — intervention group
Group type: EXPERIMENTAL
Intervention: Valgus Control Instruction (VCI) exercises
Number of subjects: 64
Study 29025837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 at a dose of 10^9 colony-forming units, orally, once daily for 6 months.
Number of subjects: 96